ClinicalTrials.gg
Active, not recruitingNCT05268094COMPASSUpdated Jan 7, 2026

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

An interventional study of Ductal Arterial Stent and Systemic-to-Pulmonary Artery Shunt in Congenital Heart Disease in Children, sponsored by Carelon Research. Active, not recruiting at 24 sites in 2 countries. Open to participants aged 1 Day to 30 Days. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Carelon Research · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
1 Day to 30 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Heart Defects, Congenital by Carelon Research — 2 open to participants now, 4 under way, 1 of them phase 3. Heart Defects, Congenital · Carelon Research.

Started
2022
with 1 other
No phase
5 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Heart Defects, Congenital by Carelon Research, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 8th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

2 of the 10 studies in Heart Defects, Congenital by Carelon Research are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 1 Day to 30 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Defects, Congenital by Carelon Research, or all of them as a file.
02

Study summary

COMPASS is a prospective multicenter randomized interventional trial. Participants with ductal-dependent pulmonary blood flow will be randomized to receive either a systemic-to-pulmonary artery shunt or ductal artery stent. Block randomization will be performed by center and by single vs. two ventricle status. Participants will be followed through the first year of life.

Read the detailed description

In neonates with ductal-dependent blood flow there remains valid uncertainty regarding the comparative benefits of ductal artery stent (DAS) with the traditional systemic-to-pulmonary artery shunt (SPS) palliation due to the lack of previous multicenter studies. COMPASS is a prospective multicenter randomized interventional trial where participants will be randomized to receive either an SPS or DAS to compare rates of a composite major morbidity/mortality endpoint in the first year of life. The study objectives are to perform an intention-to-treat analysis of participants' outcomes, and to describe the failure rate for neonatal candidates for DAS and the impact of this failure on the post-SPS course. Participants will be followed through the first year of life.

03

Conditions studied

  • Congenital Heart Disease in Children

Keywords

  • Congenital Heart Disease
  • Ductal Dependent Pulmonary Blood Flow
  • Ductal Artery Shunt
  • Systemic-to-Pulmonary Artery Shunt
04

Who can participate

Ages eligible
1 Day to 30 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Neonates with Congenital Heart Disease (CHD) and ductal-dependent pulmonary blood flow requiring only a stable source of pulmonary blood flow as the initial palliation, for whom the clinical decision is made at the enrolling center that this is best achieved by either DAS or SPS.
  2. Age ≤ 30 days at time of index procedure (DAS or SPS).

Exclusion criteria

Exclusion Criteria:

  • 1. Any patient for whom the clinical decision at the enrolling center is that an initial intervention other than DAS or SPS is indicated (e.g., Right Ventricle-Pulmonary Artery (RV-PA) conduit, Right Ventricular Outflow Tract (RVOT) stent, primary complete anatomic repair, etc.).

    2. Pulmonary Atresia with Intact Ventricular Septum (PA/IVS) where Right Ventricle (RV) decompression is planned.

    3. Presence of MAPCAs: defined as an aortopulmonary collateral that is expected to require unifocalization.

    4. Non-confluent Pulmonary Arteries (i.e., isolated Pulmonary Artery (PA) of ductal origin).

    5. Acutely jeopardized branch Pulmonary Arteries (>75% narrowing of proximal PA based on screening cross sectional imaging [Computed Tomography Angiography (CTA) or cardiovascular Magnetic Resonance (cMR)]).

    6. Bilateral Patent Ductus Arteriosis (PDA). 7. Patient who, at the time of enrollment, is deemed not to be a candidate for eventual Glenn or Complete Surgical Repair (CSR) for any reason.

    8. Birth weight \<2.0 kg. 9. Gestational age \<34 weeks at birth. 10. Patient for whom additional intervention is expected concomitant with, or prior to, DAS or SPS (e.g., atrial septostomy, aortic arch intervention, or RV outflow tract intervention) - except for branch PA arterioplasty or stent/balloon angioplasty.

    11. Major co-morbidities which, in the opinion of the investigator, would negatively alter expected 1-year survival (e.g., intracranial hemorrhage, renal failure, etc.).

    12. Specific known genetic anomaly which, in the opinion of the investigator, would be expected to significantly alter clinical course in the first year of life (e.g., Trisomy 13/18, CHARGE, VACTERL).

    13. Patient who does not plan to return to the enrolling center or another participating center for Glenn/CSR.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ductal Artery Stent

    Transcatheter ductal artery shunt will be placed by the interventional team. Drug-eluting coronary stent brand, length, and diameter are determined by the interventional team.

    Device: Ductal Arterial Stent

  • Experimental
    Systemic-to-Pulmonary Artery Shunt

    Surgical systemic-to-pulmonary artery shunt performed by the interventional team. SPS diameter, length, and material will be determined by the surgeon performing the intervention.

    Procedure: Systemic-to-Pulmonary Artery Shunt

Interventions

  • DeviceDuctal Arterial Stent

    Drug-eluting ductal arterial stents will be placed by transcatheter method.

    Also known as: Medtronic Resolute Onyx, Boston Scientific Promus Elite/Premier, Boston Scientific Synergy, Cordis Elunir, Abbott Xience

  • ProcedureSystemic-to-Pulmonary Artery Shunt

    A surgical connection will be made between a systemic artery and the pulmonary artery.

06

What researchers measure

Primary outcomes

  1. Morbidity and/or Mortality Endpoint

    Rates of a composite major morbidity and/or mortality endpoint in the first year of life will be compared between neonates with ductal-dependent pulmonary blood flow randomized to receive either DAS or SPS as the initial palliation.

    Time frame: 1 year

Secondary outcomes

  1. Global Rank Score

    All participants will be assigned a Global Rank Score, which is a rank based on a pre-specified hierarchical ranking of outcomes. This combines various endpoints into a single quantifiable endpoint with weighting of the severity of the component endpoints, and allows for the inclusion of endpoints of different forms. Global rank scores will range from 1-7.

    Time frame: 1 year

  2. Freedom from Adverse Events

    Safety, defined as freedom from procedural adverse events and complications, will be tracked and evaluated.

    Time frame: 1 year

  3. Days Alive out of Hospital

    Days alive out of the hospital represents a patient-centered outcome, and functions as a composite endpoint.

    Time frame: 1 year

07

Study locations

24 sites
08

References and documents

Publications

  • Reddy D, Kleinloog R, Kinsley R. Pulmonary Atresia, Ventricular Septal Defect, and Major Aortopulmonary Collateral Arteries: The Natural History and Late Presentation. World J Pediatr Congenit Heart Surg. 2025 Mar;16(2):203-207. doi: 10.1177/21501351241311882. Epub 2025 Feb 4. PubMed 39905870 ↗
  • Petit CJ, Romano JC, Zampi JD, Pasquali SK, McCracken CE, Chanani NK, Les AS, Burns KM, Crosby-Thompson A, Stylianou M, Kato B, Glatz AC; Pediatric Heart Network Investigators. Rationale and design of the randomized COmparison of Methods for Pulmonary blood flow Augmentation: Shunt versus Stent (COMPASS) trial: A Pediatric Heart Network study. Catheter Cardiovasc Interv. 2024 Oct;104(4):637-647. doi: 10.1002/ccd.31109. Epub 2024 Sep 23. PubMed 39311092 ↗
  • Petit CJ, Romano JC, Zampi JD, Pasquali SK, McCracken CE, Chanani NK, Les AS, Burns KM, Crosby-Thompson A, Stylianou M, Kato B, Glatz AC; Pediatric Heart Network Investigators. Rationale and Design of the Randomized COmparison of Methods for Pulmonary Blood Flow Augmentation: Shunt Versus Stent (COMPASS) Trial: A Pediatric Heart Network Study. World J Pediatr Congenit Heart Surg. 2024 Nov;15(6):693-702. doi: 10.1177/21501351241266110. Epub 2024 Sep 23. PubMed 39308140 ↗

Individual participant data

Plan to share: Yes — All individual participant data collected by the Data Coordinating Center will be shared after posting of results and main study results publication.

Supporting information: Study protocol, Informed consent form

Time frame: Protocol and Informed Consent Form will be shared within 12 months of publication of study results. Public Use Dataset will be made available after publication, timeframe to be decided.

Access criteria: Protocol and Informed Consent Form will be made available with results on clinicaltrials.gov. Public Use Dataset will be available on the Pediatric Heart Network public website and may be used in accordance with Pediatric Heart Network governance.

Data sharing details ↗ · www.pediatricheartnetwork.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Sep 2027, 62 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 62 months is above that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Mar 7, 2022
StartActual
Jun 2, 2022
Primary completionEst.
Sep 1, 2027
CompletionEst.
Feb 29, 2028
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05268094
Lead sponsor
Carelon Research
Collaborators
Pediatric Heart Network
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Jun 2, 2022
Primary completion
Sep 1, 2027 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Jan 7, 2026

Study contacts

Christopher Petit, MD
study chair · Columbia University
Andrew Glatz, MD
study chair · Washington University School of Medicine
Sara Pasquali, MD
study chair · University of Michigan
Jenna Romano, MD
study chair · University of Michigan
Jeffrey Zampi, MD
study chair · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion